Scynexis (SCYX) Total Current Liabilities (2013 - 2026)
Scynexis (SCYX) posted Total Current Liabilities of $15.9 million for Q1 2026, up 177.29% on a QoQ basis from $5.7 million in Q4 2025, and up 77.51% year-over-year from $9.0 million in Q1 2025.
Scynexis (SCYX) Total Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $15.9 million for Q1 2026.
- Quarterly Total Current Liabilities rose 77.51% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.9 million (up 77.51% YoY) and the FY2025 annual result came in at $5.7 million, down 76.21% from the prior year.
- Total Current Liabilities was $15.9 million for Q1 2026 at Scynexis, up from $5.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $45.6 million in Q1 2023 and bottomed at $5.7 million in Q4 2025.
- A 5-year average of $18.1 million and a median of $16.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 252.63% — and 2025, when it slumped 76.21%.
- Scynexis' Total Current Liabilities stood at $17.6 million in 2022, then retreated by 7.46% to $16.3 million in 2023, then soared by 47.82% to $24.1 million in 2024, then slumped by 76.21% to $5.7 million in 2025, then jumped by 177.29% to $15.9 million in 2026.
- Business Quant data shows SCYX's Total Current Liabilities at $15.9 million in Q1 2026, $5.7 million in Q4 2025, and $8.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.90 Mn |
| Dec 31, 2025 | 5.73 Mn |
| Sep 30, 2025 | 8.47 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 8.96 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 30, 2024 | 25.72 Mn |
| Jun 30, 2024 | 25.23 Mn |
| Mar 31, 2024 | 27.35 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 16.79 Mn |
| Jun 30, 2023 | 16.16 Mn |
| Mar 31, 2023 | 45.64 Mn |
| Dec 31, 2022 | 17.62 Mn |
| Sep 30, 2022 | 14.26 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 12.94 Mn |
| Dec 31, 2021 | 13.62 Mn |
| Sep 30, 2021 | 13.22 Mn |
| Jun 30, 2021 | 19.88 Mn |